Recruiting
Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Sponsor:

Alexion Pharmaceuticals, Inc.

Code:

NCT06291376

Conditions

Immunoglobulin A Nephropathy

IgAN

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ravulizumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-27. This information was provided to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc. on 2025-03-25.